IE69018B1 - Stable microbubbles suspensions injectable into living organisms - Google Patents
Stable microbubbles suspensions injectable into living organismsInfo
- Publication number
- IE69018B1 IE69018B1 IE104891A IE104891A IE69018B1 IE 69018 B1 IE69018 B1 IE 69018B1 IE 104891 A IE104891 A IE 104891A IE 104891 A IE104891 A IE 104891A IE 69018 B1 IE69018 B1 IE 69018B1
- Authority
- IE
- Ireland
- Prior art keywords
- suspension
- gas
- air
- phospholipid
- microbubbles
- Prior art date
Links
- 239000000725 suspension Substances 0.000 title claims abstract description 72
- 239000002502 liposome Substances 0.000 claims abstract description 55
- 239000004094 surface-active agent Substances 0.000 claims abstract description 46
- 239000003381 stabilizer Substances 0.000 claims abstract description 13
- 238000003384 imaging method Methods 0.000 claims abstract description 10
- 239000002872 contrast media Substances 0.000 claims abstract description 6
- 239000000243 solution Substances 0.000 claims description 48
- 239000007788 liquid Substances 0.000 claims description 44
- 239000000203 mixture Substances 0.000 claims description 36
- 238000000034 method Methods 0.000 claims description 30
- 150000003904 phospholipids Chemical class 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 18
- 150000002632 lipids Chemical class 0.000 claims description 18
- 238000009472 formulation Methods 0.000 claims description 14
- 239000007787 solid Substances 0.000 claims description 14
- 239000002245 particle Substances 0.000 claims description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
- 239000007864 aqueous solution Substances 0.000 claims description 11
- 239000003623 enhancer Substances 0.000 claims description 11
- 238000004108 freeze drying Methods 0.000 claims description 10
- 235000012000 cholesterol Nutrition 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 9
- -1 phytosterol Chemical compound 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 9
- 239000008365 aqueous carrier Substances 0.000 claims description 8
- 230000015572 biosynthetic process Effects 0.000 claims description 8
- 150000001720 carbohydrates Chemical class 0.000 claims description 8
- 235000014633 carbohydrates Nutrition 0.000 claims description 8
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 8
- 229930195729 fatty acid Natural products 0.000 claims description 8
- 239000000194 fatty acid Substances 0.000 claims description 8
- 150000004665 fatty acids Chemical class 0.000 claims description 8
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 claims description 6
- 150000002148 esters Chemical class 0.000 claims description 6
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 6
- 235000000346 sugar Nutrition 0.000 claims description 6
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims description 5
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 5
- 238000004090 dissolution Methods 0.000 claims description 5
- 150000002170 ethers Chemical class 0.000 claims description 5
- 229920001477 hydrophilic polymer Polymers 0.000 claims description 5
- 229920001184 polypeptide Polymers 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 150000008163 sugars Chemical class 0.000 claims description 5
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 claims description 4
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 claims description 4
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 claims description 4
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 4
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 claims description 4
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 claims description 4
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 claims description 4
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 4
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 4
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 claims description 4
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 claims description 4
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 4
- RNPXCFINMKSQPQ-UHFFFAOYSA-N dicetyl hydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCOP(O)(=O)OCCCCCCCCCCCCCCCC RNPXCFINMKSQPQ-UHFFFAOYSA-N 0.000 claims description 4
- 229940093541 dicetylphosphate Drugs 0.000 claims description 4
- 239000006185 dispersion Substances 0.000 claims description 4
- 150000004676 glycans Polymers 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 229920005862 polyol Polymers 0.000 claims description 4
- 150000003077 polyols Chemical class 0.000 claims description 4
- 229920006395 saturated elastomer Polymers 0.000 claims description 4
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 claims description 4
- 235000015500 sitosterol Nutrition 0.000 claims description 4
- 229950005143 sitosterol Drugs 0.000 claims description 4
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 claims description 4
- 238000002604 ultrasonography Methods 0.000 claims description 4
- BQPPJGMMIYJVBR-UHFFFAOYSA-N (10S)-3c-Acetoxy-4.4.10r.13c.14t-pentamethyl-17c-((R)-1.5-dimethyl-hexen-(4)-yl)-(5tH)-Delta8-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C BQPPJGMMIYJVBR-UHFFFAOYSA-N 0.000 claims description 3
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 claims description 3
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 claims description 3
- CHGIKSSZNBCNDW-UHFFFAOYSA-N (3beta,5alpha)-4,4-Dimethylcholesta-8,24-dien-3-ol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21 CHGIKSSZNBCNDW-UHFFFAOYSA-N 0.000 claims description 3
- XYTLYKGXLMKYMV-UHFFFAOYSA-N 14alpha-methylzymosterol Natural products CC12CCC(O)CC1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C XYTLYKGXLMKYMV-UHFFFAOYSA-N 0.000 claims description 3
- FPTJELQXIUUCEY-UHFFFAOYSA-N 3beta-Hydroxy-lanostan Natural products C1CC2C(C)(C)C(O)CCC2(C)C2C1C1(C)CCC(C(C)CCCC(C)C)C1(C)CC2 FPTJELQXIUUCEY-UHFFFAOYSA-N 0.000 claims description 3
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 claims description 3
- 239000004322 Butylated hydroxytoluene Substances 0.000 claims description 3
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims description 3
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 claims description 3
- 108010010803 Gelatin Proteins 0.000 claims description 3
- BKLIAINBCQPSOV-UHFFFAOYSA-N Gluanol Natural products CC(C)CC=CC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(O)C(C)(C)C4CC3 BKLIAINBCQPSOV-UHFFFAOYSA-N 0.000 claims description 3
- LOPKHWOTGJIQLC-UHFFFAOYSA-N Lanosterol Natural products CC(CCC=C(C)C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 LOPKHWOTGJIQLC-UHFFFAOYSA-N 0.000 claims description 3
- CAHGCLMLTWQZNJ-UHFFFAOYSA-N Nerifoliol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C CAHGCLMLTWQZNJ-UHFFFAOYSA-N 0.000 claims description 3
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims description 3
- 229940095259 butylated hydroxytoluene Drugs 0.000 claims description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 3
- QBSJHOGDIUQWTH-UHFFFAOYSA-N dihydrolanosterol Natural products CC(C)CCCC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 QBSJHOGDIUQWTH-UHFFFAOYSA-N 0.000 claims description 3
- 239000002961 echo contrast media Substances 0.000 claims description 3
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 claims description 3
- 229920000159 gelatin Polymers 0.000 claims description 3
- 239000008273 gelatin Substances 0.000 claims description 3
- 235000019322 gelatine Nutrition 0.000 claims description 3
- 235000011852 gelatine desserts Nutrition 0.000 claims description 3
- CAHGCLMLTWQZNJ-RGEKOYMOSA-N lanosterol Chemical compound C([C@]12C)C[C@@H](O)C(C)(C)[C@H]1CCC1=C2CC[C@]2(C)[C@H]([C@H](CCC=C(C)C)C)CC[C@@]21C CAHGCLMLTWQZNJ-RGEKOYMOSA-N 0.000 claims description 3
- 229940058690 lanosterol Drugs 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 3
- 210000000056 organ Anatomy 0.000 claims description 3
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 3
- 150000003905 phosphatidylinositols Chemical class 0.000 claims description 3
- 235000010388 propyl gallate Nutrition 0.000 claims description 3
- 239000000473 propyl gallate Substances 0.000 claims description 3
- 229940075579 propyl gallate Drugs 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 235000010384 tocopherol Nutrition 0.000 claims description 3
- 239000011732 tocopherol Substances 0.000 claims description 3
- 229960001295 tocopherol Drugs 0.000 claims description 3
- 229930003799 tocopherol Natural products 0.000 claims description 3
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 3
- 239000007900 aqueous suspension Substances 0.000 claims description 2
- 229920001515 polyalkylene glycol Polymers 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- 239000002195 soluble material Substances 0.000 claims description 2
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims 2
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims 2
- 150000001298 alcohols Chemical class 0.000 claims 2
- 235000010385 ascorbyl palmitate Nutrition 0.000 claims 2
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 claims 2
- 150000002482 oligosaccharides Polymers 0.000 claims 2
- 150000004804 polysaccharides Polymers 0.000 claims 2
- 102000009027 Albumins Human genes 0.000 claims 1
- 108010088751 Albumins Proteins 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 229940102213 injectable suspension Drugs 0.000 claims 1
- 239000002198 insoluble material Substances 0.000 claims 1
- XQZXYNRDCRIARQ-LURJTMIESA-N iopamidol Chemical compound C[C@H](O)C(=O)NC1=C(I)C(C(=O)NC(CO)CO)=C(I)C(C(=O)NC(CO)CO)=C1I XQZXYNRDCRIARQ-LURJTMIESA-N 0.000 claims 1
- 229960004647 iopamidol Drugs 0.000 claims 1
- 239000011236 particulate material Substances 0.000 claims 1
- 229920001059 synthetic polymer Polymers 0.000 claims 1
- 239000008346 aqueous phase Substances 0.000 abstract description 7
- 239000007789 gas Substances 0.000 description 55
- 239000010408 film Substances 0.000 description 13
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 9
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 9
- 239000011324 bead Substances 0.000 description 9
- 239000008101 lactose Substances 0.000 description 9
- 239000000787 lecithin Substances 0.000 description 9
- 235000010445 lecithin Nutrition 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 7
- 229930006000 Sucrose Natural products 0.000 description 7
- 239000000654 additive Substances 0.000 description 7
- 239000011859 microparticle Substances 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 239000005720 sucrose Substances 0.000 description 7
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 6
- 238000013019 agitation Methods 0.000 description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 6
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 210000002216 heart Anatomy 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000008223 sterile water Substances 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 4
- 229920002307 Dextran Polymers 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 239000008344 egg yolk phospholipid Substances 0.000 description 4
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 244000068988 Glycine max Species 0.000 description 3
- 235000010469 Glycine max Nutrition 0.000 description 3
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000003792 electrolyte Substances 0.000 description 3
- 150000002191 fatty alcohols Chemical class 0.000 description 3
- 229930182830 galactose Natural products 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 150000002334 glycols Chemical class 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 239000008347 soybean phospholipid Substances 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- MEUAVGJWGDPTLF-UHFFFAOYSA-N 4-(5-benzenesulfonylamino-1-methyl-1h-benzoimidazol-2-ylmethyl)-benzamidine Chemical compound N=1C2=CC(NS(=O)(=O)C=3C=CC=CC=3)=CC=C2N(C)C=1CC1=CC=C(C(N)=N)C=C1 MEUAVGJWGDPTLF-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 239000001273 butane Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- JBKVHLHDHHXQEQ-UHFFFAOYSA-N epsilon-caprolactam Chemical compound O=C1CCCCCN1 JBKVHLHDHHXQEQ-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- 150000002433 hydrophilic molecules Chemical class 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 210000005240 left ventricle Anatomy 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 239000010695 polyglycol Substances 0.000 description 2
- 229920000151 polyglycol Polymers 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 235000021251 pulses Nutrition 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000005241 right ventricle Anatomy 0.000 description 2
- 238000005204 segregation Methods 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000000859 sublimation Methods 0.000 description 2
- 230000008022 sublimation Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 description 1
- LRYZPFWEZHSTHD-HEFFAWAOSA-O 2-[[(e,2s,3r)-2-formamido-3-hydroxyoctadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium Chemical class CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](NC=O)COP(O)(=O)OCC[N+](C)(C)C LRYZPFWEZHSTHD-HEFFAWAOSA-O 0.000 description 1
- 238000011265 2D-echocardiography Methods 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- RFSDQDHHBKYQOD-UHFFFAOYSA-N 6-cyclohexylmethyloxy-2-(4'-hydroxyanilino)purine Chemical compound C1=CC(O)=CC=C1NC1=NC(OCC2CCCCC2)=C(N=CN2)C2=N1 RFSDQDHHBKYQOD-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- UCTLRSWJYQTBFZ-UHFFFAOYSA-N Dehydrocholesterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCCC(C)C)CCC33)C)C3=CC=C21 UCTLRSWJYQTBFZ-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920005372 Plexiglas® Polymers 0.000 description 1
- 239000004142 Polyoxypropylene-polyoxyethylene polymer Substances 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000001174 endocardium Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229940025708 injectable product Drugs 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000009549 lung scintigraphy Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000009206 nuclear medicine Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- UPHWVVKYDQHTCF-UHFFFAOYSA-N octadecylazanium;acetate Chemical compound CC(O)=O.CCCCCCCCCCCCCCCCCCN UPHWVVKYDQHTCF-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 108010014241 oxypolygelatine Proteins 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920001583 poly(oxyethylated polyols) Polymers 0.000 description 1
- 229920001281 polyalkylene Polymers 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920005597 polymer membrane Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 235000019338 polyoxypropylene-polyoxyethylene polymer Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 229940066675 ricinoleate Drugs 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
- A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
- A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
- A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
- A61K49/227—Liposomes, lipoprotein vesicles, e.g. LDL or HDL lipoproteins, micelles, e.g. phospholipidic or polymeric
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP90810262 | 1990-04-02 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IE911048A1 IE911048A1 (en) | 1991-10-09 |
| IE69018B1 true IE69018B1 (en) | 1996-07-24 |
Family
ID=8205915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE104891A IE69018B1 (en) | 1990-04-02 | 1991-03-28 | Stable microbubbles suspensions injectable into living organisms |
Country Status (19)
Families Citing this family (340)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020150539A1 (en) * | 1989-12-22 | 2002-10-17 | Unger Evan C. | Ultrasound imaging and treatment |
| US5705187A (en) * | 1989-12-22 | 1998-01-06 | Imarx Pharmaceutical Corp. | Compositions of lipids and stabilizing materials |
| US5228446A (en) * | 1989-12-22 | 1993-07-20 | Unger Evan C | Gas filled liposomes and their use as ultrasonic contrast agents |
| US5773024A (en) * | 1989-12-22 | 1998-06-30 | Imarx Pharmaceutical Corp. | Container with multi-phase composition for use in diagnostic and therapeutic applications |
| US5334381A (en) * | 1989-12-22 | 1994-08-02 | Unger Evan C | Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same |
| US6551576B1 (en) * | 1989-12-22 | 2003-04-22 | Bristol-Myers Squibb Medical Imaging, Inc. | Container with multi-phase composition for use in diagnostic and therapeutic applications |
| US5469854A (en) | 1989-12-22 | 1995-11-28 | Imarx Pharmaceutical Corp. | Methods of preparing gas-filled liposomes |
| US5580575A (en) | 1989-12-22 | 1996-12-03 | Imarx Pharmaceutical Corp. | Therapeutic drug delivery systems |
| US6146657A (en) | 1989-12-22 | 2000-11-14 | Imarx Pharmaceutical Corp. | Gas-filled lipid spheres for use in diagnostic and therapeutic applications |
| US5656211A (en) * | 1989-12-22 | 1997-08-12 | Imarx Pharmaceutical Corp. | Apparatus and method for making gas-filled vesicles of optimal size |
| US6088613A (en) | 1989-12-22 | 2000-07-11 | Imarx Pharmaceutical Corp. | Method of magnetic resonance focused surgical and therapeutic ultrasound |
| US5542935A (en) * | 1989-12-22 | 1996-08-06 | Imarx Pharmaceutical Corp. | Therapeutic delivery systems related applications |
| US5088499A (en) * | 1989-12-22 | 1992-02-18 | Unger Evan C | Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same |
| US5776429A (en) | 1989-12-22 | 1998-07-07 | Imarx Pharmaceutical Corp. | Method of preparing gas-filled microspheres using a lyophilized lipids |
| US5733572A (en) | 1989-12-22 | 1998-03-31 | Imarx Pharmaceutical Corp. | Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles |
| US5585112A (en) * | 1989-12-22 | 1996-12-17 | Imarx Pharmaceutical Corp. | Method of preparing gas and gaseous precursor-filled microspheres |
| US5305757A (en) | 1989-12-22 | 1994-04-26 | Unger Evan C | Gas filled liposomes and their use as ultrasonic contrast agents |
| US6001335A (en) | 1989-12-22 | 1999-12-14 | Imarx Pharmaceutical Corp. | Contrasting agents for ultrasonic imaging and methods for preparing the same |
| US5352435A (en) * | 1989-12-22 | 1994-10-04 | Unger Evan C | Ionophore containing liposomes for ultrasound imaging |
| US5922304A (en) * | 1989-12-22 | 1999-07-13 | Imarx Pharmaceutical Corp. | Gaseous precursor filled microspheres as magnetic resonance imaging contrast agents |
| US6613306B1 (en) | 1990-04-02 | 2003-09-02 | Bracco International B.V. | Ultrasound contrast agents and methods of making and using them |
| US5445813A (en) * | 1992-11-02 | 1995-08-29 | Bracco International B.V. | Stable microbubble suspensions as enhancement agents for ultrasound echography |
| US7083778B2 (en) * | 1991-05-03 | 2006-08-01 | Bracco International B.V. | Ultrasound contrast agents and methods of making and using them |
| USRE39146E1 (en) | 1990-04-02 | 2006-06-27 | Bracco International B.V. | Long-lasting aqueous dispersions or suspensions of pressure-resistant gas-filled microvesicles and methods for the preparation thereof |
| US20010024638A1 (en) * | 1992-11-02 | 2001-09-27 | Michel Schneider | Stable microbubble suspensions as enhancement agents for ultrasound echography and dry formulations thereof |
| IN172208B (US07261876-20070828-C00048.png) * | 1990-04-02 | 1993-05-01 | Sint Sa | |
| US5578292A (en) | 1991-11-20 | 1996-11-26 | Bracco International B.V. | Long-lasting aqueous dispersions or suspensions of pressure-resistant gas-filled microvesicles and methods for the preparation thereof |
| US20040208826A1 (en) * | 1990-04-02 | 2004-10-21 | Bracco International B.V. | Ultrasound contrast agents and methods of making and using them |
| US6989141B2 (en) * | 1990-05-18 | 2006-01-24 | Bracco International B.V. | Ultrasound contrast agents and methods of making and using them |
| US5556610A (en) * | 1992-01-24 | 1996-09-17 | Bracco Research S.A. | Gas mixtures useful as ultrasound contrast media, contrast agents containing the media and method |
| AU636481B2 (en) * | 1990-05-18 | 1993-04-29 | Bracco International B.V. | Polymeric gas or air filled microballoons usable as suspensions in liquid carriers for ultrasonic echography |
| US20030194376A1 (en) * | 1990-05-18 | 2003-10-16 | Bracco International B.V. | Ultrasound contrast agents and methods of making and using them |
| US5562099A (en) * | 1990-10-05 | 1996-10-08 | Massachusetts Institute Of Technology | Polymeric microparticles containing agents for imaging |
| DE4100470A1 (de) * | 1991-01-09 | 1992-07-16 | Byk Gulden Lomberg Chem Fab | Echokontrastmittel |
| US5370901A (en) | 1991-02-15 | 1994-12-06 | Bracco International B.V. | Compositions for increasing the image contrast in diagnostic investigations of the digestive tract of patients |
| GB9106686D0 (en) * | 1991-03-28 | 1991-05-15 | Hafslund Nycomed As | Improvements in or relating to contrast agents |
| GB9106673D0 (en) * | 1991-03-28 | 1991-05-15 | Hafslund Nycomed As | Improvements in or relating to contrast agents |
| US5205290A (en) * | 1991-04-05 | 1993-04-27 | Unger Evan C | Low density microspheres and their use as contrast agents for computed tomography |
| US5874062A (en) | 1991-04-05 | 1999-02-23 | Imarx Pharmaceutical Corp. | Methods of computed tomography using perfluorocarbon gaseous filled microspheres as contrast agents |
| US5993805A (en) | 1991-04-10 | 1999-11-30 | Quadrant Healthcare (Uk) Limited | Spray-dried microparticles and their use as therapeutic vehicles |
| GB9107628D0 (en) * | 1991-04-10 | 1991-05-29 | Moonbrook Limited | Preparation of diagnostic agents |
| US6875420B1 (en) | 1991-09-17 | 2005-04-05 | Amersham Health As | Method of ultrasound imaging |
| US5409688A (en) * | 1991-09-17 | 1995-04-25 | Sonus Pharmaceuticals, Inc. | Gaseous ultrasound contrast media |
| RU2114637C1 (ru) * | 1991-09-17 | 1998-07-10 | Сонус Фармасьютикалз, Инк. | Биосовместимая контрастная среда и способ получения ультразвукового изображения |
| US6723303B1 (en) | 1991-09-17 | 2004-04-20 | Amersham Health, As | Ultrasound contrast agents including protein stabilized microspheres of perfluoropropane, perfluorobutane or perfluoropentane |
| MX9205298A (es) * | 1991-09-17 | 1993-05-01 | Steven Carl Quay | Medios gaseosos de contraste de ultrasonido y metodo para seleccionar gases para usarse como medios de contraste de ultrasonido |
| GB9200388D0 (en) * | 1992-01-09 | 1992-02-26 | Nycomed As | Improvements in or relating to contrast agents |
| GB9200387D0 (en) * | 1992-01-09 | 1992-02-26 | Nycomed As | Improvements in or relating to contrast agents |
| IL104084A (en) * | 1992-01-24 | 1996-09-12 | Bracco Int Bv | Sustainable aqueous suspensions of pressure-resistant and gas-filled blisters, their preparation, and contrast agents containing them |
| GB9221329D0 (en) | 1992-10-10 | 1992-11-25 | Delta Biotechnology Ltd | Preparation of further diagnostic agents |
| EP0690708A1 (en) * | 1992-12-02 | 1996-01-10 | Unilever Plc | Cosmetic composition |
| ATE200985T1 (de) * | 1993-01-25 | 2001-05-15 | Sonus Pharma Inc | Phase-stift kolloide zur verwendung als ultraschallkontrastmittel |
| IL108416A (en) | 1993-01-25 | 1998-10-30 | Sonus Pharma Inc | Colloids with phase difference as contrast ultrasound agents |
| US5558855A (en) * | 1993-01-25 | 1996-09-24 | Sonus Pharmaceuticals | Phase shift colloids as ultrasound contrast agents |
| US5701899A (en) * | 1993-05-12 | 1997-12-30 | The Board Of Regents Of The University Of Nebraska | Perfluorobutane ultrasound contrast agent and methods for its manufacture and use |
| US5695740A (en) * | 1993-05-12 | 1997-12-09 | The Board Of Regents Of The University Of Nebraska | Perfluorocarbon ultrasound contrast agent comprising microbubbles containing a filmogenic protein and a saccharide |
| US5716597A (en) * | 1993-06-04 | 1998-02-10 | Molecular Biosystems, Inc. | Emulsions as contrast agents and method of use |
| US5855865A (en) * | 1993-07-02 | 1999-01-05 | Molecular Biosystems, Inc. | Method for making encapsulated gas microspheres from heat denatured protein in the absence of oxygen gas |
| US5798091A (en) | 1993-07-30 | 1998-08-25 | Alliance Pharmaceutical Corp. | Stabilized gas emulsion containing phospholipid for ultrasound contrast enhancement |
| CA2164813C (en) | 1993-07-30 | 2009-11-24 | Ernest G. Schutt | Stabilized microbubble compositions for ultrasound |
| GB9318288D0 (en) * | 1993-09-03 | 1993-10-20 | Nycomed Imaging As | Improvements in or relating to contrast agents |
| US7083572B2 (en) * | 1993-11-30 | 2006-08-01 | Bristol-Myers Squibb Medical Imaging, Inc. | Therapeutic delivery systems |
| AU679295B2 (en) | 1993-12-15 | 1997-06-26 | Bracco Suisse S.A. | Gas mixtures useful as ultrasound contrast media |
| DE4406474A1 (de) | 1994-02-23 | 1995-08-24 | Schering Ag | Gas enthaltende Mikropartikel, diese enthaltende Mittel, deren Verwendung in der Ultraschalldiagnostik, sowie Verfahren zur Herstellung der Partikel und Mittel |
| US5736121A (en) | 1994-05-23 | 1998-04-07 | Imarx Pharmaceutical Corp. | Stabilized homogenous suspensions as computed tomography contrast agents |
| US5730955A (en) * | 1994-08-02 | 1998-03-24 | Molecular Biosystems, Inc. | Process for making gas-filled microspheres containing a liquid hydrophobic barrier |
| US5965109A (en) * | 1994-08-02 | 1999-10-12 | Molecular Biosystems, Inc. | Process for making insoluble gas-filled microspheres containing a liquid hydrophobic barrier |
| US5540909A (en) * | 1994-09-28 | 1996-07-30 | Alliance Pharmaceutical Corp. | Harmonic ultrasound imaging with microbubbles |
| GB9423419D0 (en) | 1994-11-19 | 1995-01-11 | Andaris Ltd | Preparation of hollow microcapsules |
| US6743779B1 (en) | 1994-11-29 | 2004-06-01 | Imarx Pharmaceutical Corp. | Methods for delivering compounds into a cell |
| IL116328A (en) * | 1994-12-16 | 1999-09-22 | Bracco Research Sa | Frozen suspension of gas microbubbles in frozen aqueous carrier for use as contrast agent in ultrasonic imaging |
| TW319763B (US07261876-20070828-C00048.png) | 1995-02-01 | 1997-11-11 | Epix Medical Inc | |
| US5830430A (en) | 1995-02-21 | 1998-11-03 | Imarx Pharmaceutical Corp. | Cationic lipids and the use thereof |
| US5560364A (en) * | 1995-05-12 | 1996-10-01 | The Board Of Regents Of The University Of Nebraska | Suspended ultra-sound induced microbubble cavitation imaging |
| US5997898A (en) * | 1995-06-06 | 1999-12-07 | Imarx Pharmaceutical Corp. | Stabilized compositions of fluorinated amphiphiles for methods of therapeutic delivery |
| US6139819A (en) | 1995-06-07 | 2000-10-31 | Imarx Pharmaceutical Corp. | Targeted contrast agents for diagnostic and therapeutic use |
| ATE265863T1 (de) * | 1995-06-07 | 2004-05-15 | Imarx Pharmaceutical Corp | Neue zielgerichtete mittel zur diagnostischen und therapeutischen verwendung |
| US6231834B1 (en) | 1995-06-07 | 2001-05-15 | Imarx Pharmaceutical Corp. | Methods for ultrasound imaging involving the use of a contrast agent and multiple images and processing of same |
| WO2004073750A1 (en) | 1995-06-07 | 2004-09-02 | Harald Dugstad | Improvements in or relating to contrast agents |
| US6521211B1 (en) * | 1995-06-07 | 2003-02-18 | Bristol-Myers Squibb Medical Imaging, Inc. | Methods of imaging and treatment with targeted compositions |
| US6033645A (en) | 1996-06-19 | 2000-03-07 | Unger; Evan C. | Methods for diagnostic imaging by regulating the administration rate of a contrast agent |
| US5804162A (en) * | 1995-06-07 | 1998-09-08 | Alliance Pharmaceutical Corp. | Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients |
| US5648098A (en) * | 1995-10-17 | 1997-07-15 | The Board Of Regents Of The University Of Nebraska | Thrombolytic agents and methods of treatment for thrombosis |
| CA2244767C (en) * | 1996-01-24 | 2005-11-22 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Process for the production of powdered pulmonary surfactant preparations |
| EE04224B1 (et) * | 1996-02-19 | 2004-02-16 | Nycomed Imaging As | Gaasi mikromullide dispersioon ja selle lüofiliseeritud jääk, ultraheli kontrastaine ja selle valmistamismeetod, mikromulle eraldav maatriks ning ultraheli kontrastaine kompositsioon |
| US6165442A (en) * | 1996-02-19 | 2000-12-26 | Nycomed Imaging As | Thermally stabilized ultrasound contrast agent |
| US5611344A (en) * | 1996-03-05 | 1997-03-18 | Acusphere, Inc. | Microencapsulated fluorinated gases for use as imaging agents |
| US6245747B1 (en) | 1996-03-12 | 2001-06-12 | The Board Of Regents Of The University Of Nebraska | Targeted site specific antisense oligodeoxynucleotide delivery method |
| CA2252617A1 (en) | 1996-05-01 | 1997-11-06 | Imarx Pharmaceutical Corp. | Methods for delivering compounds into a cell |
| US5849727A (en) | 1996-06-28 | 1998-12-15 | Board Of Regents Of The University Of Nebraska | Compositions and methods for altering the biodistribution of biological agents |
| US5837221A (en) * | 1996-07-29 | 1998-11-17 | Acusphere, Inc. | Polymer-lipid microencapsulated gases for use as imaging agents |
| GB9617811D0 (en) | 1996-08-27 | 1996-10-09 | Nycomed Imaging As | Improvements in or relating to contrast agents |
| US6414139B1 (en) | 1996-09-03 | 2002-07-02 | Imarx Therapeutics, Inc. | Silicon amphiphilic compounds and the use thereof |
| US6017310A (en) * | 1996-09-07 | 2000-01-25 | Andaris Limited | Use of hollow microcapsules |
| US5846517A (en) | 1996-09-11 | 1998-12-08 | Imarx Pharmaceutical Corp. | Methods for diagnostic imaging using a renal contrast agent and a vasodilator |
| DK0977597T3 (da) | 1996-09-11 | 2003-05-05 | Imarx Pharmaceutical Corp | Forbedrede fremgangsmåder til diagnostisk billeddannelse ved hjælp af et kontrastmiddel og en vasodilatator. |
| US6261537B1 (en) * | 1996-10-28 | 2001-07-17 | Nycomed Imaging As | Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors |
| CN1238700A (zh) * | 1996-10-28 | 1999-12-15 | 奈科姆成像有限公司 | 诊断和/或治疗剂的改进或与其相关的改进 |
| WO1998018496A2 (en) * | 1996-10-28 | 1998-05-07 | Nycomed Imaging As | Contrast agents |
| ES2206689T3 (es) * | 1996-10-28 | 2004-05-16 | Amersham Health As | Agentes de contraste. |
| CZ149499A3 (cs) | 1996-10-28 | 1999-09-15 | Nycomed Imaging As | Diagnostický a/nebo léčebný prostředek |
| US20070036722A1 (en) * | 1996-10-28 | 2007-02-15 | Pal Rongved | Separation processes |
| WO1998018501A2 (en) * | 1996-10-28 | 1998-05-07 | Marsden, John, Christopher | Improvements in or relating to diagnostic/therapeutic agents |
| EP0991427A2 (en) * | 1996-10-28 | 2000-04-12 | Marsden, John Christopher | Improvements in or relating to diagnostic/therapeutic agents |
| US6331289B1 (en) | 1996-10-28 | 2001-12-18 | Nycomed Imaging As | Targeted diagnostic/therapeutic agents having more than one different vectors |
| US6068600A (en) * | 1996-12-06 | 2000-05-30 | Quadrant Healthcare (Uk) Limited | Use of hollow microcapsules |
| US6537246B1 (en) * | 1997-06-18 | 2003-03-25 | Imarx Therapeutics, Inc. | Oxygen delivery agents and uses for the same |
| US6090800A (en) | 1997-05-06 | 2000-07-18 | Imarx Pharmaceutical Corp. | Lipid soluble steroid prodrugs |
| US6120751A (en) | 1997-03-21 | 2000-09-19 | Imarx Pharmaceutical Corp. | Charged lipids and uses for the same |
| US6143276A (en) | 1997-03-21 | 2000-11-07 | Imarx Pharmaceutical Corp. | Methods for delivering bioactive agents to regions of elevated temperatures |
| US20050019266A1 (en) * | 1997-05-06 | 2005-01-27 | Unger Evan C. | Novel targeted compositions for diagnostic and therapeutic use |
| US6416740B1 (en) | 1997-05-13 | 2002-07-09 | Bristol-Myers Squibb Medical Imaging, Inc. | Acoustically active drug delivery systems |
| US6245318B1 (en) * | 1997-05-27 | 2001-06-12 | Mallinckrodt Inc. | Selectively binding ultrasound contrast agents |
| AU7702798A (en) | 1997-05-30 | 1998-12-30 | Alliance Pharmaceutical Corporation | Methods and apparatus for monitoring and quantifying the movement of fluid |
| CA2268324C (en) * | 1997-08-12 | 2007-06-12 | Bracco Research S.A. | Administrable compositions and methods for magnetic resonance imaging |
| US6001333A (en) * | 1997-09-12 | 1999-12-14 | See; Jackie R. | Methods of preparing micro encapsulated agents for use in the detection of tumors by CT imaging |
| US6548047B1 (en) | 1997-09-15 | 2003-04-15 | Bristol-Myers Squibb Medical Imaging, Inc. | Thermal preactivation of gaseous precursor filled compositions |
| US20060165606A1 (en) | 1997-09-29 | 2006-07-27 | Nektar Therapeutics | Pulmonary delivery particles comprising water insoluble or crystalline active agents |
| US6309623B1 (en) * | 1997-09-29 | 2001-10-30 | Inhale Therapeutic Systems, Inc. | Stabilized preparations for use in metered dose inhalers |
| US6565885B1 (en) * | 1997-09-29 | 2003-05-20 | Inhale Therapeutic Systems, Inc. | Methods of spray drying pharmaceutical compositions |
| US6050943A (en) | 1997-10-14 | 2000-04-18 | Guided Therapy Systems, Inc. | Imaging, therapy, and temperature monitoring ultrasonic system |
| US6623430B1 (en) | 1997-10-14 | 2003-09-23 | Guided Therapy Systems, Inc. | Method and apparatus for safety delivering medicants to a region of tissue using imaging, therapy and temperature monitoring ultrasonic system |
| US6726650B2 (en) * | 1997-12-04 | 2004-04-27 | Bracco Research S.A. | Automatic liquid injection system and method |
| US6123923A (en) | 1997-12-18 | 2000-09-26 | Imarx Pharmaceutical Corp. | Optoacoustic contrast agents and methods for their use |
| US20010003580A1 (en) | 1998-01-14 | 2001-06-14 | Poh K. Hui | Preparation of a lipid blend and a phospholipid suspension containing the lipid blend |
| US6537520B1 (en) | 1998-03-31 | 2003-03-25 | Bristol-Myers Squibb Pharma Company | Pharmaceuticals for the imaging of angiogenic disorders |
| US6524553B2 (en) | 1998-03-31 | 2003-02-25 | Bristol-Myers Squibb Pharma Company | Quinolone vitronectin receptor antagonist pharmaceuticals |
| US6548663B1 (en) | 1998-03-31 | 2003-04-15 | Bristol-Myers Squibb Pharma Company | Benzodiazepine vitronectin receptor antagonist pharmaceuticals |
| CN1295578A (zh) | 1998-03-31 | 2001-05-16 | 杜邦药品公司 | 用于血管生成性疾病成像的药物 |
| US6794518B1 (en) | 1998-12-18 | 2004-09-21 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
| CA2727746A1 (en) | 1998-12-18 | 2000-06-22 | Bristol-Myers Squibb Pharma Company | Quinolone vitronectin receptor antagonist pharmaceuticals |
| US6569402B1 (en) | 1998-12-18 | 2003-05-27 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
| TR200101757T2 (tr) | 1998-12-18 | 2001-12-21 | Dupont Pharmaceuticais Company | Vitronektin reseptör antagonisti farmasötikler |
| US6511649B1 (en) | 1998-12-18 | 2003-01-28 | Thomas D. Harris | Vitronectin receptor antagonist pharmaceuticals |
| US6444192B1 (en) | 1999-02-05 | 2002-09-03 | The Regents Of The University Of California | Diagnostic imaging of lymph structures |
| ES2243270T3 (es) * | 1999-05-21 | 2005-12-01 | Mallinckrodt Inc. | Dispositivo de resuspension de un agente de contraste. |
| WO2000072757A1 (en) * | 1999-06-01 | 2000-12-07 | Drexel University | Surface stabilized microbubbles for use in ultrasound contrast and drug delivery agents |
| US7192698B1 (en) * | 1999-08-17 | 2007-03-20 | Purdue Research Foundation | EphA2 as a diagnostic target for metastatic cancer |
| US7220401B2 (en) * | 1999-09-24 | 2007-05-22 | Barnes-Jewish Hospital | Blood clot-targeted nanoparticles |
| US20030144570A1 (en) * | 1999-11-12 | 2003-07-31 | Angiotech Pharmaceuticals, Inc. | Compositions and methods for treating disease utilizing a combination of radioactive therapy and cell-cycle inhibitors |
| US7871598B1 (en) | 2000-05-10 | 2011-01-18 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
| US8404217B2 (en) | 2000-05-10 | 2013-03-26 | Novartis Ag | Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use |
| TWI290473B (en) | 2000-05-10 | 2007-12-01 | Alliance Pharma | Phospholipid-based powders for drug delivery |
| CA2410887C (en) | 2000-06-02 | 2012-07-24 | Bracco Research Usa | Compounds for targeting endothelial cells, compositions containing the same and methods for their use |
| AU2001280934A1 (en) * | 2000-07-28 | 2002-02-13 | Alliance Pharmaceutical Corp. | Methods and compositions to upregulate, redirect or limit immune responses to bioactive compounds |
| WO2004026111A2 (en) | 2000-11-16 | 2004-04-01 | Microspherix Llc | Flexible and/or elastic brachytherapy seed or strand |
| US7914453B2 (en) | 2000-12-28 | 2011-03-29 | Ardent Sound, Inc. | Visual imaging system for ultrasonic probe |
| GB0102691D0 (en) | 2001-02-02 | 2001-03-21 | Nestle Sa | Water soluable powders and tablets |
| DE10108799A1 (de) * | 2001-02-19 | 2002-09-05 | Laser & Med Tech Gmbh | Verfahren und Vorrichtung zur Ultraschallimpfung von biologischem Zellmaterial |
| AU2002253454A1 (en) * | 2001-04-06 | 2002-10-21 | Bracco Research S.A. | Method for improved measurement of local physical parameters in afluid-filled cavity |
| ATE508735T1 (de) | 2001-12-19 | 2011-05-15 | Novartis Ag | Pulmonale verabreichung von aminoglykosiden |
| US7261876B2 (en) | 2002-03-01 | 2007-08-28 | Bracco International Bv | Multivalent constructs for therapeutic and diagnostic applications |
| US8623822B2 (en) | 2002-03-01 | 2014-01-07 | Bracco Suisse Sa | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy |
| US7794693B2 (en) * | 2002-03-01 | 2010-09-14 | Bracco International B.V. | Targeting vector-phospholipid conjugates |
| EP1587944A4 (en) | 2002-03-01 | 2007-03-21 | Dyax Corp | KDR AND VEGF / KDR BINDING PEPTIDES AND THEIR USE FOR DIAGNOSTIC AND THERAPEUTIC PURPOSES |
| ES2398393T3 (es) | 2002-03-01 | 2013-03-15 | Dyax Corp. | Péptidos de unión a KDR y a VEGF/KDR y su uso en diagnóstico y terapia |
| US7211240B2 (en) | 2002-03-01 | 2007-05-01 | Bracco International B.V. | Multivalent constructs for therapeutic and diagnostic applications |
| DE10211886B4 (de) * | 2002-03-18 | 2004-07-15 | Dornier Medtech Gmbh | Verfahren und Einrichtung zum Erzeugen bipolarer akustischer Impulse |
| US20040126400A1 (en) * | 2002-05-03 | 2004-07-01 | Iversen Patrick L. | Delivery of therapeutic compounds via microparticles or microbubbles |
| DE10223196B4 (de) * | 2002-05-24 | 2004-05-13 | Dornier Medtech Systems Gmbh | Verfahren und Einrichtung zum Transferieren von Molekülen in Zellen |
| US20040018237A1 (en) * | 2002-05-31 | 2004-01-29 | Perricone Nicholas V. | Topical drug delivery using phosphatidylcholine |
| US6803046B2 (en) * | 2002-08-16 | 2004-10-12 | Bracco International B.V. | Sincalide formulations |
| AU2003266884A1 (en) * | 2002-09-16 | 2004-04-30 | Vasogen Ireland Limited | Accelerating recovery from trauma |
| US20070128117A1 (en) * | 2003-02-04 | 2007-06-07 | Bracco International B.V. | Ultrasound contrast agents and process for the preparation thereof |
| DK1590006T3 (da) * | 2003-02-04 | 2010-12-20 | Bracco Suisse Sa | Ultralydskontrastmidler og fremgangsmåde til frembringelse deraf |
| US20060235296A1 (en) | 2003-02-13 | 2006-10-19 | Bracco Imaging S.P.A. | Contrast enhanced x-ray phase imaging |
| PL2949658T3 (pl) | 2003-03-03 | 2018-11-30 | Dyax Corp. | PEPTYDY SPECYFICZNIE WIĄŻĄCE SIĘ Z RECEPTOREM HGF (cMET) I ICH ZASTOSOWANIA |
| US20040258760A1 (en) * | 2003-03-20 | 2004-12-23 | Wheatley Margaret A. | Isolated nanocapsule populations and surfactant-stabilized microcapsules and nanocapsules for diagnostic imaging and drug delivery and methods for their production |
| ITFI20030077A1 (it) * | 2003-03-26 | 2004-09-27 | Actis Active Sensors S R L | Metodo per l'indagine ecografica tramite mezzi di contrasto |
| WO2004091397A2 (en) * | 2003-04-15 | 2004-10-28 | Philips Intellectual Property & Standards Gmbh | Method of determining state variables and changes in state variables |
| US8021303B2 (en) | 2003-06-12 | 2011-09-20 | Bracco Research Sa | System for extracting morphological information through a perfusion assessment process |
| JP4706003B2 (ja) | 2003-06-12 | 2011-06-22 | ブラッコ・シュイス・ソシエテ・アノニム | 超音波造影画像において補充曲線フィッティングを用いる血流評価法 |
| US20060222694A1 (en) * | 2003-06-27 | 2006-10-05 | Oh Choon K | Stabilized topotecan liposomal composition and methods |
| US7744852B2 (en) | 2003-07-25 | 2010-06-29 | Rubicor Medical, Llc | Methods and systems for marking post biopsy cavity sites |
| US7537788B2 (en) | 2003-07-25 | 2009-05-26 | Rubicor Medical, Inc. | Post-biopsy cavity treatment implants and methods |
| US20050020899A1 (en) | 2003-07-25 | 2005-01-27 | Rubicor Medical, Inc. | Post-biopsy cavity treatmetn implants and methods |
| US7358226B2 (en) * | 2003-08-27 | 2008-04-15 | The Regents Of The University Of California | Ultrasonic concentration of drug delivery capsules |
| DE10353780A1 (de) * | 2003-11-18 | 2005-06-23 | Beiersdorf Ag | Partikel aus fester Hülle und potenziell feuchtigkeitsempfindliche oder wasserunlösliche Wirkstoffe enthaltendem flüssigem Kern, Zubereitungen diese enthaltend und Verfahren zu ihrer Herstellung |
| JP2005154282A (ja) * | 2003-11-20 | 2005-06-16 | Mebiopharm Co Ltd | ガス封入リポソームの製造法 |
| NO20035401D0 (no) * | 2003-12-04 | 2003-12-04 | Amersham Health As | Metode |
| CA2545362C (en) * | 2003-12-22 | 2013-02-12 | Bracco Research Sa | Assembly of gas-filled microvesicle with active component for contrast imaging |
| CN100563718C (zh) * | 2003-12-22 | 2009-12-02 | 伯拉考开发股份有限公司 | 用于反差成像的充气微囊组件 |
| CN1321697C (zh) * | 2003-12-23 | 2007-06-20 | 中国人民解放军军事医学科学院毒物药物研究所 | 一种以磷脂类成分为成膜材料的超声造影剂组合物及其制备方法 |
| EP1715897B2 (en) | 2004-01-20 | 2013-10-30 | Sunnybrook and Women's College Health Sciences Centre | High frequency ultrasound imaging using contrast agents |
| US8357351B2 (en) | 2004-04-21 | 2013-01-22 | Ananth Annapragada | Nano-scale contrast agents and methods of use |
| US7713517B2 (en) | 2004-04-21 | 2010-05-11 | Marval Biosciences, Inc. | Compositions and methods for enhancing contrast in imaging |
| US8012457B2 (en) | 2004-06-04 | 2011-09-06 | Acusphere, Inc. | Ultrasound contrast agent dosage formulation |
| GB2417080B (en) | 2004-08-13 | 2008-05-21 | Stichting Tech Wetenschapp | Intravascular ultrasound techniques |
| CN101005858A (zh) | 2004-08-18 | 2007-07-25 | 伯拉考开发股份有限公司 | 用于反差成像的充气微泡组合物 |
| US7393325B2 (en) | 2004-09-16 | 2008-07-01 | Guided Therapy Systems, L.L.C. | Method and system for ultrasound treatment with a multi-directional transducer |
| US7824348B2 (en) | 2004-09-16 | 2010-11-02 | Guided Therapy Systems, L.L.C. | System and method for variable depth ultrasound treatment |
| US9011336B2 (en) | 2004-09-16 | 2015-04-21 | Guided Therapy Systems, Llc | Method and system for combined energy therapy profile |
| US8444562B2 (en) | 2004-10-06 | 2013-05-21 | Guided Therapy Systems, Llc | System and method for treating muscle, tendon, ligament and cartilage tissue |
| US8535228B2 (en) | 2004-10-06 | 2013-09-17 | Guided Therapy Systems, Llc | Method and system for noninvasive face lifts and deep tissue tightening |
| US10864385B2 (en) | 2004-09-24 | 2020-12-15 | Guided Therapy Systems, Llc | Rejuvenating skin by heating tissue for cosmetic treatment of the face and body |
| EP1879502A2 (en) * | 2004-10-06 | 2008-01-23 | Guided Therapy Systems, L.L.C. | Method and system for cosmetic enhancement |
| PT2409728T (pt) | 2004-10-06 | 2017-11-16 | Guided Therapy Systems Llc | Sistema para o tratamento de tecidos por ultrassons |
| US9827449B2 (en) | 2004-10-06 | 2017-11-28 | Guided Therapy Systems, L.L.C. | Systems for treating skin laxity |
| US11883688B2 (en) | 2004-10-06 | 2024-01-30 | Guided Therapy Systems, Llc | Energy based fat reduction |
| US9694212B2 (en) | 2004-10-06 | 2017-07-04 | Guided Therapy Systems, Llc | Method and system for ultrasound treatment of skin |
| US7758524B2 (en) | 2004-10-06 | 2010-07-20 | Guided Therapy Systems, L.L.C. | Method and system for ultra-high frequency ultrasound treatment |
| US8133180B2 (en) | 2004-10-06 | 2012-03-13 | Guided Therapy Systems, L.L.C. | Method and system for treating cellulite |
| US20060111744A1 (en) | 2004-10-13 | 2006-05-25 | Guided Therapy Systems, L.L.C. | Method and system for treatment of sweat glands |
| US11235179B2 (en) | 2004-10-06 | 2022-02-01 | Guided Therapy Systems, Llc | Energy based skin gland treatment |
| US8690779B2 (en) | 2004-10-06 | 2014-04-08 | Guided Therapy Systems, Llc | Noninvasive aesthetic treatment for tightening tissue |
| US11724133B2 (en) | 2004-10-07 | 2023-08-15 | Guided Therapy Systems, Llc | Ultrasound probe for treatment of skin |
| US11207548B2 (en) | 2004-10-07 | 2021-12-28 | Guided Therapy Systems, L.L.C. | Ultrasound probe for treating skin laxity |
| EP1671627B8 (en) * | 2004-12-15 | 2010-04-07 | Dornier MedTech Systems GmbH | Improvement of cell therapy and tissue regeneration in patients with cardiovascular and neurological diseases by means of shockwaves |
| EP1853333A1 (en) * | 2004-12-23 | 2007-11-14 | Bracco Research S.A. | Liquid transfer device for medical dispensing containers |
| CN100556368C (zh) | 2004-12-23 | 2009-11-04 | 伯拉考开发股份有限公司 | 基于弹丸注射的灌注评价方法和系统 |
| US7846100B2 (en) | 2005-03-03 | 2010-12-07 | Bracco International Bv | Medical imaging system based on a targeted contrast agent |
| EP1714642A1 (en) * | 2005-04-18 | 2006-10-25 | Bracco Research S.A. | Pharmaceutical composition comprising gas-filled microcapsules for ultrasound mediated delivery |
| JP4695188B2 (ja) | 2005-04-25 | 2011-06-08 | アーデント サウンド， インコーポレイテッド | コンピュータ周辺機器の安全性を向上させるための方法および装置 |
| AU2005332157A1 (en) * | 2005-05-23 | 2006-11-30 | Mebiopharm Co., Ltd., | Method of producing liposomes containing gas enclosed therein |
| JP2009515578A (ja) | 2005-11-10 | 2009-04-16 | ブラッコ・リサーチ・ソシエテ・アノニム | 画像化アプリケーションの造影剤濃度の即時の可視化 |
| CN101304690B (zh) | 2005-11-10 | 2011-06-08 | 伯拉考国际股份公司 | 基于流体力学分析在医学成像应用中检测固定造影剂 |
| BRPI0619522B8 (pt) | 2005-12-09 | 2021-07-27 | Bracco Suisse Sa | conjugados de objetivação de vetor-fosfolipídio, composição compreendendo os referidos conjugados, composição de agente de contraste para ultra-som e método para preparo de microvesícula cheia de gás compreendendo um fosfolipídio e de fabricação de conjugado de peptídeo-fosfolipídio tendo baixos níveis de tfa |
| EP1797919A1 (en) * | 2005-12-16 | 2007-06-20 | Bracco Research S.A. | Liquid transfer device for medical dispensing containers |
| WO2008016992A1 (en) | 2006-08-01 | 2008-02-07 | Scimed Life Systems, Inc. | Pulse inversion sequences for nonlinear imaging |
| US9446156B2 (en) | 2006-09-05 | 2016-09-20 | Bracco Suisse S.A. | Gas-filled microvesicles with polymer-modified lipids |
| US9566454B2 (en) | 2006-09-18 | 2017-02-14 | Guided Therapy Systems, Llc | Method and sysem for non-ablative acne treatment and prevention |
| US7976743B2 (en) * | 2006-10-16 | 2011-07-12 | Northwestern University | Gas-containing liposomes |
| WO2008058200A2 (en) * | 2006-11-08 | 2008-05-15 | St. Lawrence Nanotechnology, Inc. | Method and apparatus for electrochemical mechanical polishing nip substrates |
| EP2117603A2 (en) | 2006-12-19 | 2009-11-18 | Bracco International B.V. | Targeting and therapeutic compounds and gas-filled microvesicles comprising said compounds |
| JP5313915B2 (ja) | 2006-12-21 | 2013-10-09 | ブラッコ・シュイス・ソシエテ・アノニム | 医用画像用途における固定化された造影剤の脱離の検知 |
| TWI526233B (zh) | 2007-05-07 | 2016-03-21 | 指導治療系統股份有限公司 | 利用聲波能量調製藥劑輸送及效能之系統 |
| US20150174388A1 (en) | 2007-05-07 | 2015-06-25 | Guided Therapy Systems, Llc | Methods and Systems for Ultrasound Assisted Delivery of a Medicant to Tissue |
| US8052001B2 (en) * | 2007-05-10 | 2011-11-08 | Delta Electronics, Inc. | Case assembly structure of electronic device |
| WO2009042621A2 (en) * | 2007-09-24 | 2009-04-02 | Mallinckrodt Inc. | Injection system having microbubble-enhanced extravasation detection system |
| US8642013B2 (en) * | 2007-12-05 | 2014-02-04 | Ananth Annapragada | Nano-scale contrast agents and methods of use |
| JP5524860B2 (ja) | 2007-12-28 | 2014-06-18 | ブラッコ・シュイス・ソシエテ・アノニム | 医療画像用途における固定化された造影剤の定量分析 |
| US10130342B2 (en) | 2007-12-28 | 2018-11-20 | Bracco Suisse Sa | Initialization of fitting parameters for perfusion assessment based on bolus administration |
| EP2090322A1 (en) | 2008-02-18 | 2009-08-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of fsh receptor ligands for diagnosis and therapy of cancer |
| EP3170888A1 (en) | 2008-05-23 | 2017-05-24 | Siwa Corporation | Methods and compositions for facilitating regeneration |
| PL3058875T3 (pl) | 2008-06-06 | 2022-11-21 | Ulthera, Inc. | System do zabiegu kosmetycznego i obrazowania |
| WO2009152445A1 (en) * | 2008-06-13 | 2009-12-17 | Marval Biosciences, Inc. | Imaging of atherosclerotic plaques using liposomal imaging agents |
| GB0811856D0 (en) * | 2008-06-27 | 2008-07-30 | Ucl Business Plc | Magnetic microbubbles, methods of preparing them and their uses |
| US9192685B2 (en) * | 2008-10-07 | 2015-11-24 | Bracco Suisse S.A. | Targeting construct comprising anti-polymer antibody and contrast/therapeutic agents binding to the same |
| US20110045095A1 (en) * | 2008-10-08 | 2011-02-24 | The Regents Of The University Of California | Polymer-phospholipid shelled microbubbles |
| EP2189112A1 (en) | 2008-11-24 | 2010-05-26 | Bracco Research S.A. | Real-time perfusion imaging and quantification |
| CN102245229B (zh) | 2008-12-16 | 2013-04-24 | 博莱科瑞士股份有限公司 | 用于推注造影剂的装置 |
| CA2748362A1 (en) | 2008-12-24 | 2010-07-01 | Michael H. Slayton | Methods and systems for fat reduction and/or cellulite treatment |
| WO2010123918A1 (en) | 2009-04-20 | 2010-10-28 | Drexel University | Encapsulation of microbubbles within the aqueous core of microcapsules |
| JP5593382B2 (ja) | 2009-06-08 | 2014-09-24 | ブラッコ・シュイス・ソシエテ・アノニム | パラメトリック画像の自動スケーリング |
| WO2011025893A1 (en) * | 2009-08-28 | 2011-03-03 | The Trustees Of Columbia University In The City Of New York | Systems, methods, and devices for production of gas-filled microbubbles |
| CA2769164C (en) | 2009-09-01 | 2017-11-07 | Bracco Suisse Sa | Parametric images based on dynamic behavior over time |
| US9107950B2 (en) | 2009-09-15 | 2015-08-18 | The Trustees Of Columbia University In The City Of New York | Systems, methods, and devices for microbubbles |
| US8715186B2 (en) | 2009-11-24 | 2014-05-06 | Guided Therapy Systems, Llc | Methods and systems for generating thermal bubbles for improved ultrasound imaging and therapy |
| WO2011084694A1 (en) | 2009-12-17 | 2011-07-14 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Stabilized stat3 decoy oligonucleotides and uses therefor |
| EP2345732A1 (en) | 2010-01-19 | 2011-07-20 | Universite Paris Descartes | Methods for intracellular delivery of nucleic acids |
| WO2011091160A1 (en) * | 2010-01-20 | 2011-07-28 | Henry Wu | Custom-formulated phospholipid microbubbles and methods and uses thereof |
| EP2544593B1 (en) | 2010-03-09 | 2014-12-31 | Bracco Suisse SA | Initialization of fitting parameters for perfusion assessment based on bolus administration |
| US9504446B2 (en) | 2010-08-02 | 2016-11-29 | Guided Therapy Systems, Llc | Systems and methods for coupling an ultrasound source to tissue |
| US9149658B2 (en) | 2010-08-02 | 2015-10-06 | Guided Therapy Systems, Llc | Systems and methods for ultrasound treatment |
| US9265483B2 (en) | 2010-08-06 | 2016-02-23 | The Trustees Of Columbia University In The City Of New York | Medical imaging contrast devices, methods, and systems |
| EP3338807B1 (en) | 2010-08-09 | 2020-12-16 | Bracco Suisse SA | Targeting construct for gas-filled microvesicles |
| ES2515467T3 (es) | 2010-08-09 | 2014-10-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Métodos y composiciones farmacéuticas para el tratamiento de una enfermedad ocular en un sujeto |
| EP2621534B1 (en) | 2010-09-27 | 2019-03-13 | Siwa Corporation | Selective removal of age-modified cells for treatment of atherosclerosis |
| US8857438B2 (en) | 2010-11-08 | 2014-10-14 | Ulthera, Inc. | Devices and methods for acoustic shielding |
| US8721571B2 (en) | 2010-11-22 | 2014-05-13 | Siwa Corporation | Selective removal of cells having accumulated agents |
| EP2654788B1 (en) | 2010-12-24 | 2018-03-14 | Bracco Suisse SA | Gas-filled microvesicles for use as vaccine |
| EP2474327A1 (en) | 2011-01-07 | 2012-07-11 | RWTH Aachen | Microdosing of ultrasound contrast agents |
| DE102011005444A1 (de) * | 2011-03-11 | 2012-09-13 | Innora Gmbh | Festes, negatives Röntgenkontrastmittel zur Darstellung des Gastrointestinaltraktes |
| JP2014508166A (ja) | 2011-03-17 | 2014-04-03 | トランスダーマル バイオテクノロジ インコーポレーテッド | 局所的一酸化窒素システム及びその使用方法 |
| WO2012136813A2 (en) | 2011-04-07 | 2012-10-11 | Universitetet I Oslo | Agents for medical radar diagnosis |
| KR102068724B1 (ko) | 2011-07-10 | 2020-01-21 | 가이디드 테라피 시스템스, 엘.엘.씨. | 에너지원으로 초음파를 이용한 피부 외양을 개선하는 시스템 및 방법 |
| EP2545908A1 (en) | 2011-07-11 | 2013-01-16 | RWTH Aachen | Medium for microbubbles or microparticles and preparation thereof |
| KR20190080967A (ko) | 2011-07-11 | 2019-07-08 | 가이디드 테라피 시스템스, 엘.엘.씨. | 조직에 초음파원을 연결하는 시스템 및 방법 |
| US9263663B2 (en) | 2012-04-13 | 2016-02-16 | Ardent Sound, Inc. | Method of making thick film transducer arrays |
| US8871260B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Methods and compositions for muscular and neuromuscular diseases |
| US8871255B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Treatment of skin and soft tissue infection with nitric oxide |
| US8871254B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system |
| US8871256B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Methods and systems for treatment of inflammatory diseases with nitric oxide |
| US8871259B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Techniques and systems for treatment of neuropathic pain and other indications |
| US8871262B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Compositions and methods for treatment of osteoporosis and other indications |
| US8871261B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Cancer treatments and compositions for use thereof |
| US8871257B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Prevention and treatment of cardiovascular diseases using systems and methods for transdermal nitric oxide delivery |
| US8871258B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Treatment and prevention of learning and memory disorders |
| US9510802B2 (en) | 2012-09-21 | 2016-12-06 | Guided Therapy Systems, Llc | Reflective ultrasound technology for dermatological treatments |
| WO2014096165A2 (en) | 2012-12-21 | 2014-06-26 | Bracco Suisse Sa | Gas-filled microvesicles |
| US9734584B2 (en) | 2012-12-21 | 2017-08-15 | Bracco Suisse Sa | Segmentation in diagnostic imaging applications based on statistical analysis over time |
| CN113648552A (zh) | 2013-03-08 | 2021-11-16 | 奥赛拉公司 | 用于多焦点超声治疗的装置和方法 |
| US9687520B2 (en) | 2013-03-13 | 2017-06-27 | Transdermal Biotechnology, Inc. | Memory or learning improvement using peptide and other compositions |
| US20140271731A1 (en) | 2013-03-13 | 2014-09-18 | Transdermal Biotechnology, Inc. | Cardiovascular disease treatment and prevention |
| US9314423B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Hair treatment systems and methods using peptides and other compositions |
| US9295637B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Compositions and methods for affecting mood states |
| US9393265B2 (en) | 2013-03-13 | 2016-07-19 | Transdermal Biotechnology, Inc. | Wound healing using topical systems and methods |
| US20140271938A1 (en) | 2013-03-13 | 2014-09-18 | Transdermal Biotechnology, Inc. | Systems and methods for delivery of peptides |
| US9320758B2 (en) | 2013-03-13 | 2016-04-26 | Transdermal Biotechnology, Inc. | Brain and neural treatments comprising peptides and other compositions |
| US9849160B2 (en) | 2013-03-13 | 2017-12-26 | Transdermal Biotechnology, Inc. | Methods and systems for treating or preventing cancer |
| US9314422B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Peptide systems and methods for metabolic conditions |
| US9724419B2 (en) | 2013-03-13 | 2017-08-08 | Transdermal Biotechnology, Inc. | Peptide systems and methods for metabolic conditions |
| US9320706B2 (en) | 2013-03-13 | 2016-04-26 | Transdermal Biotechnology, Inc. | Immune modulation using peptides and other compositions |
| US20140271937A1 (en) | 2013-03-13 | 2014-09-18 | Transdermal Biotechnology, Inc. | Brain and neural treatments comprising peptides and other compositions |
| US9295647B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Systems and methods for delivery of peptides |
| US9339457B2 (en) | 2013-03-13 | 2016-05-17 | Transdermal Biotechnology, Inc. | Cardiovascular disease treatment and prevention |
| US9387159B2 (en) | 2013-03-13 | 2016-07-12 | Transdermal Biotechnology, Inc. | Treatment of skin, including aging skin, to improve appearance |
| US9750787B2 (en) | 2013-03-13 | 2017-09-05 | Transdermal Biotechnology, Inc. | Memory or learning improvement using peptide and other compositions |
| US9314417B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Treatment of skin, including aging skin, to improve appearance |
| US9393264B2 (en) | 2013-03-13 | 2016-07-19 | Transdermal Biotechnology, Inc. | Immune modulation using peptides and other compositions |
| US9314433B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Methods and systems for treating or preventing cancer |
| US9241899B2 (en) | 2013-03-13 | 2016-01-26 | Transdermal Biotechnology, Inc. | Topical systems and methods for treating sexual dysfunction |
| US9295636B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Wound healing using topical systems and methods |
| AU2014230447A1 (en) | 2013-03-15 | 2015-09-17 | Westfaelische Wilhelms-Universitaet Muenster | Detection of acute renal allograft rejection |
| US10561862B2 (en) | 2013-03-15 | 2020-02-18 | Guided Therapy Systems, Llc | Ultrasound treatment device and methods of use |
| JP6568057B2 (ja) | 2013-07-03 | 2019-08-28 | ブラッコ スイス エス．アー． | 虚血性発作の超音波治療のための装置及び方法 |
| KR101853948B1 (ko) * | 2013-07-05 | 2018-05-02 | 사회복지법인 삼성생명공익재단 | X-선 조영제 및 기포 촉진제를 함유하는 조영 조성물 및 그 제조방법 |
| JP6523326B2 (ja) * | 2014-04-07 | 2019-05-29 | ブラッコ・シュイス・ソシエテ・アノニムＢｒａｃｃｏ Ｓｕｉｓｓｅ ＳＡ | 非基本波分析による音響レベルのＩｎ−Ｓｉｔｕ推定 |
| BR112016023889B1 (pt) | 2014-04-18 | 2023-02-07 | Ulthera, Inc | Sistema de transdução de ultrassom para ultrassom de focagem linear |
| JP6913458B2 (ja) | 2014-05-28 | 2021-08-04 | 武田薬品工業株式会社 | 抗菌水 |
| RU2721568C2 (ru) | 2014-09-19 | 2020-05-20 | Сива Корпорейшн | Анти-age антитела для лечения воспаления и аутоиммунных нарушений |
| CN104337766A (zh) * | 2014-10-09 | 2015-02-11 | 唐春林 | 一种地高辛脂质微泡及其制备方法 |
| US9993535B2 (en) | 2014-12-18 | 2018-06-12 | Siwa Corporation | Method and composition for treating sarcopenia |
| ES2726924T3 (es) | 2014-12-18 | 2019-10-10 | Bracco Suisse Sa | Formulación de microvesículas dirigidas rellenas de gas |
| US10358502B2 (en) | 2014-12-18 | 2019-07-23 | Siwa Corporation | Product and method for treating sarcopenia |
| WO2016102515A1 (en) | 2014-12-22 | 2016-06-30 | Bracco Suisse Sa | Gas-filled microvesicles for use as vaccine |
| CN107206111B (zh) | 2014-12-31 | 2021-04-27 | 蓝瑟斯医学影像公司 | 脂质封装的气体微球组合物及相关方法 |
| KR101853949B1 (ko) | 2015-01-02 | 2018-05-02 | 사회복지법인 삼성생명공익재단 | X-선 조영제 및 기포 촉진제를 함유하는 조영 조성물 및 그 제조방법 |
| WO2017097853A1 (en) | 2015-12-09 | 2017-06-15 | Koninklijke Philips N.V. | Interleaved beam pattern for sonothrombolysis and other vascular acoustic resonator mediated therapies |
| EP3386397B1 (en) | 2015-12-10 | 2020-02-05 | Bracco Suisse SA | Detection of immobilized contrast agent with dynamic thresholding |
| KR20230175327A (ko) | 2016-01-18 | 2023-12-29 | 얼테라, 인크 | 환형 초음파 어레이가 가요성 인쇄 회로 기판에 지엽적으로 전기적으로 연결된 컴팩트한 초음파 디바이스 및 그 조립 방법 |
| CA3011248A1 (en) | 2016-02-09 | 2017-08-17 | Bracco Suisse Sa | A recombinant chimeric protein for selectins targeting |
| ES2912064T3 (es) | 2016-02-19 | 2022-05-24 | Siwa Corp | Método y composición para tratar el cáncer, destruir las células cancerosas metastásicas y evitar la metástasis del cáncer usando anticuerpo para productos finales de glicación avanzada (AGE) |
| WO2017181116A1 (en) | 2016-04-15 | 2017-10-19 | Siwa Corporation | Anti-age antibodies for treating neurodegenerative disorders |
| AU2017260532A1 (en) | 2016-05-04 | 2018-11-22 | Lantheus Medical Imaging, Inc. | Methods and devices for preparation of ultrasound contrast agents |
| JP2019518763A (ja) | 2016-06-23 | 2019-07-04 | シワ コーポレーション | 様々な疾患及び障害の治療において使用するためのワクチン |
| US10342828B1 (en) * | 2016-06-27 | 2019-07-09 | Roderick M. Dayton | Fecal oxygenation |
| US9789210B1 (en) | 2016-07-06 | 2017-10-17 | Lantheus Medical Imaging, Inc. | Methods for making ultrasound contrast agents |
| CN109562279B (zh) | 2016-08-16 | 2022-03-15 | 奥赛拉公司 | 用于皮肤的美容超声治疗的系统和方法 |
| US10858449B1 (en) | 2017-01-06 | 2020-12-08 | Siwa Corporation | Methods and compositions for treating osteoarthritis |
| US10961321B1 (en) | 2017-01-06 | 2021-03-30 | Siwa Corporation | Methods and compositions for treating pain associated with inflammation |
| US10925937B1 (en) | 2017-01-06 | 2021-02-23 | Siwa Corporation | Vaccines for use in treating juvenile disorders associated with inflammation |
| US10995151B1 (en) | 2017-01-06 | 2021-05-04 | Siwa Corporation | Methods and compositions for treating disease-related cachexia |
| EP3609923A1 (en) | 2017-04-13 | 2020-02-19 | Siwa Corporation | Humanized monoclonal advanced glycation end-product antibody |
| US11110063B2 (en) | 2017-08-25 | 2021-09-07 | MAIA Pharmaceuticals, Inc. | Storage stable sincalide formulations |
| US11518801B1 (en) | 2017-12-22 | 2022-12-06 | Siwa Corporation | Methods and compositions for treating diabetes and diabetic complications |
| US11944849B2 (en) | 2018-02-20 | 2024-04-02 | Ulthera, Inc. | Systems and methods for combined cosmetic treatment of cellulite with ultrasound |
| US20200360289A1 (en) * | 2019-05-15 | 2020-11-19 | Bracco Suisse Sa | Freeze-dried product and gas-filled microvesicles suspension |
| CN111569683B (zh) * | 2020-05-14 | 2022-04-15 | 深圳市陆讯纳米科技有限公司 | 一种高浓度长效臭氧纳米气泡水溶液及制备方法 |
| CN111467266B (zh) * | 2020-05-14 | 2022-10-28 | 深圳市陆讯纳米科技有限公司 | 一种臭氧纳米气泡漱口液及制备方法 |
Family Cites Families (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE131540C (US07261876-20070828-C00048.png) * | ||||
| DE77752C (de) * | R. A. LISTER, Victoria Iron Works, u. M. PEDERSEN, Dursley, County of Gloucester, Engl | Einlafsventil mit Sieb für Milchschleudern | ||
| DE123235C (US07261876-20070828-C00048.png) * | ||||
| DE52575C (de) * | J. E. STROSCHEIN, Apotheker in Berlin S.O., Köpenickerstr. 32 | Verfahren zur Erzeugung von Mustern auf Geweben und dergl. mittels Vexirfarbten | ||
| DE320433C (de) * | 1915-07-13 | 1920-09-17 | Erich F Huth G M B H Dr | Anordnung zum Empfang elektrischer Schwingungen |
| DE327490C (de) * | 1916-05-31 | 1920-10-13 | Heinrich Schemann | Kuenstliche Hand |
| NL302030A (US07261876-20070828-C00048.png) | 1962-12-21 | 1900-01-01 | ||
| US3968203A (en) | 1965-10-01 | 1976-07-06 | Jerome G. Spitzer | Aerosol astringent composition |
| US3615972A (en) | 1967-04-28 | 1971-10-26 | Dow Chemical Co | Expansible thermoplastic polymer particles containing volatile fluid foaming agent and method of foaming the same |
| US3650831A (en) | 1969-03-10 | 1972-03-21 | Armour Dial Inc | Method of cleaning surfaces |
| US3900420A (en) | 1970-05-18 | 1975-08-19 | Felix Sebba | Microgas emulsions and method of forming same |
| US4027007A (en) | 1970-12-09 | 1977-05-31 | Colgate-Palmolive Company | Antiperspirants formulated with borax |
| GB1575343A (en) * | 1977-05-10 | 1980-09-17 | Ici Ltd | Method for preparing liposome compositions containing biologically active compounds |
| CH621479A5 (US07261876-20070828-C00048.png) * | 1977-08-05 | 1981-02-13 | Battelle Memorial Institute | |
| CH624011A5 (US07261876-20070828-C00048.png) * | 1977-08-05 | 1981-07-15 | Battelle Memorial Institute | |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4256251A (en) | 1978-04-24 | 1981-03-17 | Lawrence M. Smith | Surgical staplers and staple |
| US4192859A (en) * | 1978-09-29 | 1980-03-11 | E. R. Squibb & Sons, Inc. | Contrast media containing liposomes as carriers |
| US4276885A (en) * | 1979-05-04 | 1981-07-07 | Rasor Associates, Inc | Ultrasonic image enhancement |
| US4265251A (en) * | 1979-06-28 | 1981-05-05 | Rasor Associates, Inc. | Method of determining pressure within liquid containing vessel |
| US4316391A (en) | 1979-11-13 | 1982-02-23 | Ultra Med, Inc. | Flow rate measurement |
| DE3173476D1 (en) * | 1980-11-17 | 1986-02-20 | Schering Ag | Composition generating microbubbles |
| US4681119A (en) | 1980-11-17 | 1987-07-21 | Schering Aktiengesellschaft | Method of production and use of microbubble precursors |
| US4657756A (en) | 1980-11-17 | 1987-04-14 | Schering Aktiengesellschaft | Microbubble precursors and apparatus for their production and use |
| US4442843A (en) * | 1980-11-17 | 1984-04-17 | Schering, Ag | Microbubble precursors and methods for their production and use |
| DE3141641A1 (de) † | 1981-10-16 | 1983-04-28 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Ultraschall-kontrastmittel und dessen herstellung |
| US4718433A (en) | 1983-01-27 | 1988-01-12 | Feinstein Steven B | Contrast agents for ultrasonic imaging |
| US4572203A (en) | 1983-01-27 | 1986-02-25 | Feinstein Steven B | Contact agents for ultrasonic imaging |
| GB2135647A (en) * | 1983-02-15 | 1984-09-05 | Squibb & Sons Inc | Method of preparing liposomes and products produced thereby |
| GB2134869A (en) * | 1983-02-15 | 1984-08-22 | Squibb & Sons Inc | Method of preparing liposomes and products produced thereby |
| DE3313946A1 (de) | 1983-04-15 | 1984-10-18 | Schering AG, 1000 Berlin und 4709 Bergkamen | Mikropartikel und gasblaeschen enthaltende ultraschall-kontrastmittel |
| DE3313947A1 (de) * | 1983-04-15 | 1984-10-18 | Schering AG, 1000 Berlin und 4709 Bergkamen | Mikropartikel und gasblaeschen enthaltende ultraschall-kontrastmittel |
| US5141738A (en) | 1983-04-15 | 1992-08-25 | Schering Aktiengesellschaft | Ultrasonic contrast medium comprising gas bubbles and solid lipophilic surfactant-containing microparticles and use thereof |
| US4900540A (en) * | 1983-06-20 | 1990-02-13 | Trustees Of The University Of Massachusetts | Lipisomes containing gas for ultrasound detection |
| US4544545A (en) * | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| DE3324754A1 (de) * | 1983-07-06 | 1985-01-17 | Schering AG, 1000 Berlin und 4709 Bergkamen | Ultraschallkontrastmittel sowie dessen herstellung |
| US5618514A (en) | 1983-12-21 | 1997-04-08 | Nycomed Imaging As | Diagnostic and contrast agent |
| GB8504916D0 (en) * | 1985-02-26 | 1985-03-27 | Isc Chemicals Ltd | Emulsions of perfluorocarbons in aqueous media |
| DE3529195A1 (de) | 1985-08-14 | 1987-02-26 | Max Planck Gesellschaft | Kontrastmittel fuer ultraschalluntersuchungen und verfahren zu seiner herstellung |
| US4684479A (en) | 1985-08-14 | 1987-08-04 | Arrigo Joseph S D | Surfactant mixtures, stable gas-in-liquid emulsions, and methods for the production of such emulsions from said mixtures |
| US4927623A (en) * | 1986-01-14 | 1990-05-22 | Alliance Pharmaceutical Corp. | Dissolution of gas in a fluorocarbon liquid |
| EP0245019A3 (en) * | 1986-04-30 | 1989-05-10 | Michael A. Davis | Low density contrast medium for diagnosis of pathologic conditions |
| DE3637926C1 (de) | 1986-11-05 | 1987-11-26 | Schering Ag | Ultraschall-Manometrieverfahren in einer Fluessigkeit mittels Mikroblaeschen |
| FR2608942B1 (fr) | 1986-12-31 | 1991-01-11 | Centre Nat Rech Scient | Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanocapsules |
| US5283067A (en) * | 1987-01-30 | 1994-02-01 | Ciba-Geigy Corporation | Parenteral suspensions |
| US5089181A (en) * | 1987-02-24 | 1992-02-18 | Vestar, Inc. | Method of dehydrating vesicle preparations for long term storage |
| CH672733A5 (US07261876-20070828-C00048.png) | 1987-05-22 | 1989-12-29 | Bracco Ind Chimica Spa | |
| DE3741201A1 (de) | 1987-12-02 | 1989-06-15 | Schering Ag | Ultraschallarbeitsverfahren und mittel zu dessen durchfuehrung |
| US4844882A (en) * | 1987-12-29 | 1989-07-04 | Molecular Biosystems, Inc. | Concentrated stabilized microbubble-type ultrasonic imaging agent |
| IE61591B1 (en) * | 1987-12-29 | 1994-11-16 | Molecular Biosystems Inc | Concentrated stabilized microbubble-type ultrasonic imaging agent and method of production |
| ES2068917T3 (es) * | 1988-02-05 | 1995-05-01 | Schering Ag | Medios de contraste por ultrasonido, procedimiento para su obtencion y utilizacion de los mismos como productos de diagnostico y terapeuticos. |
| US5425366A (en) * | 1988-02-05 | 1995-06-20 | Schering Aktiengesellschaft | Ultrasonic contrast agents for color Doppler imaging |
| US5171755A (en) * | 1988-04-29 | 1992-12-15 | Hemagen/Pfc | Emulsions of highly fluorinated organic compounds |
| US5730954A (en) | 1988-08-23 | 1998-03-24 | Schering Aktiengesellschaft | Preparation comprising cavitate- or clathrate-forming host/guest complexes as contrast agent |
| DE3828905A1 (de) | 1988-08-23 | 1990-03-15 | Schering Ag | Mittel bestehend aus cavitate oder clathrate bildenden wirt/gast-komplexen als kontrastmittel |
| US4957656A (en) | 1988-09-14 | 1990-09-18 | Molecular Biosystems, Inc. | Continuous sonication method for preparing protein encapsulated microbubbles |
| DE3934656A1 (de) | 1989-10-13 | 1991-04-18 | Schering Ag | Verfahren zur herstellung von waessrigen dispersionen |
| US5776429A (en) | 1989-12-22 | 1998-07-07 | Imarx Pharmaceutical Corp. | Method of preparing gas-filled microspheres using a lyophilized lipids |
| US5228446A (en) * | 1989-12-22 | 1993-07-20 | Unger Evan C | Gas filled liposomes and their use as ultrasonic contrast agents |
| US5149319A (en) | 1990-09-11 | 1992-09-22 | Unger Evan C | Methods for providing localized therapeutic heat to biological tissues and fluids |
| US5123414A (en) * | 1989-12-22 | 1992-06-23 | Unger Evan C | Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same |
| US5209720A (en) | 1989-12-22 | 1993-05-11 | Unger Evan C | Methods for providing localized therapeutic heat to biological tissues and fluids using gas filled liposomes |
| US5088499A (en) * | 1989-12-22 | 1992-02-18 | Unger Evan C | Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same |
| DE4004430A1 (de) | 1990-02-09 | 1991-08-14 | Schering Ag | Aus polyaldehyden aufgebaute kontrastmittel |
| GB9003821D0 (en) | 1990-02-20 | 1990-04-18 | Danbiosyst Uk | Diagnostic aid |
| US5445813A (en) | 1992-11-02 | 1995-08-29 | Bracco International B.V. | Stable microbubble suspensions as enhancement agents for ultrasound echography |
| US5556610A (en) * | 1992-01-24 | 1996-09-17 | Bracco Research S.A. | Gas mixtures useful as ultrasound contrast media, contrast agents containing the media and method |
| IN172208B (US07261876-20070828-C00048.png) * | 1990-04-02 | 1993-05-01 | Sint Sa | |
| US5205287A (en) | 1990-04-26 | 1993-04-27 | Hoechst Aktiengesellschaft | Ultrasonic contrast agents, processes for their preparation and the use thereof as diagnostic and therapeutic agents |
| US5137928A (en) | 1990-04-26 | 1992-08-11 | Hoechst Aktiengesellschaft | Ultrasonic contrast agents, processes for their preparation and the use thereof as diagnostic and therapeutic agents |
| US5190982A (en) | 1990-04-26 | 1993-03-02 | Hoechst Aktiengesellschaft | Ultrasonic contrast agents, processes for their preparation and the use thereof as diagnostic and therapeutic agents |
| AU636481B2 (en) * | 1990-05-18 | 1993-04-29 | Bracco International B.V. | Polymeric gas or air filled microballoons usable as suspensions in liquid carriers for ultrasonic echography |
| US5215680A (en) * | 1990-07-10 | 1993-06-01 | Cavitation-Control Technology, Inc. | Method for the production of medical-grade lipid-coated microbubbles, paramagnetic labeling of such microbubbles and therapeutic uses of microbubbles |
| DE4100470A1 (de) | 1991-01-09 | 1992-07-16 | Byk Gulden Lomberg Chem Fab | Echokontrastmittel |
| GB9106686D0 (en) * | 1991-03-28 | 1991-05-15 | Hafslund Nycomed As | Improvements in or relating to contrast agents |
| GB9106673D0 (en) * | 1991-03-28 | 1991-05-15 | Hafslund Nycomed As | Improvements in or relating to contrast agents |
| US5874062A (en) | 1991-04-05 | 1999-02-23 | Imarx Pharmaceutical Corp. | Methods of computed tomography using perfluorocarbon gaseous filled microspheres as contrast agents |
| GB9107628D0 (en) | 1991-04-10 | 1991-05-29 | Moonbrook Limited | Preparation of diagnostic agents |
| US5147631A (en) | 1991-04-30 | 1992-09-15 | Du Pont Merck Pharmaceutical Company | Porous inorganic ultrasound contrast agents |
| US5364612A (en) | 1991-05-06 | 1994-11-15 | Immunomedics, Inc. | Detection of cardiovascular lesions |
| DK0586524T3 (US07261876-20070828-C00048.png) * | 1991-06-03 | 1997-05-20 | Nycomed Imaging As | |
| DE4127442C2 (de) | 1991-08-17 | 1996-08-22 | Udo Dr Gros | Wäßrige Dispersion Fluorcarbon enthaltender Phospholipid-Vesikel und ein Verfahren zu ihrer Herstellung |
| NZ244147A (en) | 1991-09-03 | 1994-09-27 | Hoechst Ag | Echogenic particles which comprise a gas and at least one shaping substance, and their use as diagnostic agents |
| US5409688A (en) | 1991-09-17 | 1995-04-25 | Sonus Pharmaceuticals, Inc. | Gaseous ultrasound contrast media |
| RU2114637C1 (ru) | 1991-09-17 | 1998-07-10 | Сонус Фармасьютикалз, Инк. | Биосовместимая контрастная среда и способ получения ультразвукового изображения |
| WO1993006869A1 (en) * | 1991-10-04 | 1993-04-15 | Mallinckrodt Medical, Inc. | Gaseous ultrasound contrast agents |
| GB9200388D0 (en) | 1992-01-09 | 1992-02-26 | Nycomed As | Improvements in or relating to contrast agents |
| IL104084A (en) | 1992-01-24 | 1996-09-12 | Bracco Int Bv | Sustainable aqueous suspensions of pressure-resistant and gas-filled blisters, their preparation, and contrast agents containing them |
| ATE184491T1 (de) * | 1992-03-06 | 1999-10-15 | Nycomed Imaging As | Verbesserungen in bezug auf kontrastmittel |
| WO1994009703A1 (en) * | 1992-11-02 | 1994-05-11 | Drexel University | Surfactant-stabilized microbubble mixtures, process for preparing and methods of using the same |
| US5716597A (en) | 1993-06-04 | 1998-02-10 | Molecular Biosystems, Inc. | Emulsions as contrast agents and method of use |
| AU683485B2 (en) | 1993-07-02 | 1997-11-13 | Molecular Biosystems, Inc. | Method for making encapsulated gas microspheres from heat denatured protein in the absence of oxygen gas |
| CA2164813C (en) | 1993-07-30 | 2009-11-24 | Ernest G. Schutt | Stabilized microbubble compositions for ultrasound |
| US5601085A (en) | 1995-10-02 | 1997-02-11 | Nycomed Imaging As | Ultrasound imaging |
| JP3914757B2 (ja) * | 2001-11-30 | 2007-05-16 | デュアキシズ株式会社 | ウィルス検査のための装置と方法とシステム |
-
1991
- 1991-03-26 IN IN247/MAS/91A patent/IN172208B/en unknown
- 1991-03-27 IS IS3686A patent/IS3686A7/is unknown
- 1991-03-28 NZ NZ237637A patent/NZ237637A/en unknown
- 1991-03-28 IE IE104891A patent/IE69018B1/en not_active IP Right Cessation
- 1991-03-29 IL IL9773091A patent/IL97730A/en not_active IP Right Cessation
- 1991-04-02 EP EP91907163A patent/EP0474833B2/en not_active Expired - Lifetime
- 1991-04-02 CN CN91102163A patent/CN1055413C/zh not_active Expired - Lifetime
- 1991-04-02 AT AT91907163T patent/ATE125711T1/de not_active IP Right Cessation
- 1991-04-02 KR KR1019910701733A patent/KR960002184B1/ko not_active IP Right Cessation
- 1991-04-02 ZA ZA912427A patent/ZA912427B/xx unknown
- 1991-04-02 DK DK91907163T patent/DK0474833T4/da active
- 1991-04-02 JP JP3506829A patent/JP2842453B2/ja not_active Expired - Lifetime
- 1991-04-02 US US07/775,989 patent/US5271928A/en not_active Expired - Lifetime
- 1991-04-02 CA CA002056371A patent/CA2056371C/en not_active Expired - Lifetime
- 1991-04-02 ES ES91907163T patent/ES2075438T5/es not_active Expired - Lifetime
- 1991-04-02 WO PCT/EP1991/000620 patent/WO1991015244A2/en active IP Right Grant
- 1991-04-02 DE DE69111719T patent/DE69111719T3/de not_active Expired - Lifetime
- 1991-04-02 AU AU75828/91A patent/AU630030B2/en not_active Expired
-
1993
- 1993-09-29 US US08/128,540 patent/US5380519A/en not_active Expired - Lifetime
-
1994
- 1994-09-30 US US08/315,347 patent/US5531980A/en not_active Expired - Lifetime
-
1995
- 1995-06-01 US US08/456,385 patent/US5658551A/en not_active Expired - Lifetime
- 1995-06-01 US US08/457,581 patent/US5567414A/en not_active Expired - Lifetime
- 1995-09-06 GR GR950402454T patent/GR3017324T3/el unknown
- 1995-09-26 US US08/534,198 patent/US5643553A/en not_active Expired - Lifetime
-
1997
- 1997-05-09 US US08/853,936 patent/US6110443A/en not_active Expired - Lifetime
- 1997-07-15 US US08/893,371 patent/US7033574B1/en not_active Expired - Fee Related
-
1998
- 1998-02-10 US US09/021,150 patent/US6136293A/en not_active Expired - Fee Related
- 1998-02-11 US US09/022,868 patent/US5911972A/en not_active Expired - Lifetime
- 1998-06-26 JP JP18050498A patent/JP4205779B2/ja not_active Expired - Lifetime
-
2000
- 2000-08-01 US US09/630,537 patent/US6485705B1/en not_active Expired - Fee Related
-
2002
- 2002-08-23 US US10/226,244 patent/US6896875B2/en not_active Expired - Fee Related
-
2003
- 2003-02-27 JP JP2003050459A patent/JP2003221350A/ja active Pending
-
2005
- 2005-03-22 US US11/085,169 patent/US20050207980A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5271928A (en) | Stable microbubbles suspensions injectable into living organisms | |
| FI115953B (fi) | Stabiileja mikrokuplasuspensioita vahvistusaineiksi ultraäänikaikukuvausta varten | |
| US20060257321A1 (en) | Ultrasound contrast agents and methods of making and using them | |
| US20120093732A1 (en) | Ultrasound contrast agents and methods of making and using them | |
| US20040208826A1 (en) | Ultrasound contrast agents and methods of making and using them | |
| US6613306B1 (en) | Ultrasound contrast agents and methods of making and using them | |
| US20060034771A1 (en) | Ultrasound contrast agents and methods of making and using them | |
| US20010008626A1 (en) | Ultrasound contrast agents and methods of making and using them | |
| US20030185759A1 (en) | Ultrasound contrast agents and methods of making and using them | |
| US20030194376A1 (en) | Ultrasound contrast agents and methods of making and using them | |
| US20010012507A1 (en) | Ultrasound contrast agents and methods of making and using them | |
| US20010024640A1 (en) | Ultrasound contrast agents and methods of making and using them | |
| US20030064030A1 (en) | Ultrasound contrast agents and methods of making and using them |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Patent lapsed |